Content overview: “AbbVie, Eli Lilly, Gilead Near All-Time Highs as Investors Rotate from Tech to Pharma”. Big pharma stocks are surging as a tech selloff pushes investors toward safer bets. Shares of AbbVie, Eli Lilly, and Gilead Sciences are trading at or near record highs, reflecting a broader rotation into defensive sectors. The move comes as high-flying technology names face pressure from rising rates and valuation concerns, prompting fund managers to rebalance portfolios toward healthcare companies with steady cash flows and strong pipelines.
This shift matters because it signals a change in market leadership. For months, tech giants dominated gains, but now investors are rewarding drugmakers for their resilience and innovation. Eli Lilly's weight-loss and diabetes drugs, AbbVie's immunology portfolio, and Gilead's HIV and oncology treatments are seen as reliable growth drivers even in an economic slowdown. The full version stays on the original page, which this listing opens directly.